Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Cerus (CERS) stock in plain English

Free brief · no signupStart here
CERSPublished Nov 19, 2026
Cerus Corp
Healthcare · Medical Devices
Manufactures and sells chemical pathogen reduction systems for blood platelets and plasma. Supplies disposable processing sets and illuminator hardware directly to blood collection centers.
Assets:
INTERCEPT platformFlagship system treating platelets, plasma, and red blood cells
Concord headquartersCentral administrative and clinical research facility in California
300 global employeesDedicated workforce handling regulatory compliance and direct distribution
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

52
OPS ScoreOperating finances
Latest quote
-2.06%$1.90
$383.71M
n/a (loss)
$227.05M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 19, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was CERS. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Cerus (CERS) do?

Cerus Corp (CERS) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures and sells chemical pathogen reduction systems for blood platelets and plasma. Supplies disposable processing sets and illuminator hardware directly to blood collection centers. Operates pathogen reduction technology systems that chemically treat donated blood components to prevent. It is worth $383.71M on the market and sold $227.05M over the last year.

Market cap
$383.71M
P/E ratio
None (reported a loss)
Annual sales
$227.05M
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 19, 2026

Brands and businesses behind CERS

  • INTERCEPT Blood System: Sells pathogen inactivation equipment and single-use processing kits to blood banks to prevent transfusion-transmitted infections.

CERS’s flags, in plain English

Each flag is a number from Cerus’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.

Still Climbing

Sales up 17.5% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Stupid Cash

Can pay this year's bills 2 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Wide Gross Margin

Gross margin of 51.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Burning Cash

Losing money, profit margin of -3.2%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

1 more green flag and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about CERS

How big is Cerus?

Cerus’ market cap is $383.71M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $227.05M: what customers paid the company over the last year, before any costs.

What is CERS’s P/E ratio?

CERS has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with CERS?

The business depends on a single core product line for almost all of its commercial revenue. That is one risk on Cerus’ card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Cerus’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. CERS’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card